有害事象を評価するための研究、およびIVオキサリプラチン、フルオロウラシル、フォリン酸/ロイコボリン、ベバシズマブ、ベバシズマブ、パニツムマブの成人参加者のパニツムマブと組み合わせたテリソツマブアディズテカンの静脈内(IV)の有効性を評価する研究 (AndroMETa-CRC)
転移性結腸直腸癌の被験者における複数の治療の組み合わせの安全性と有効性の安全性と有効性を評価するための第2相、無作為化、無作為化、マスタープロトコル研究
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
調査の概要
状態
条件
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:ABBVIE CALL CENTER
- 電話番号:844-663-3742
- メール:abbvieclinicaltrials@abbvie.com
研究場所
-
-
California
-
Duarte、California、アメリカ、91010
- 募集
- City of Hope National Medical Center /ID# 270255
-
Santa Monica、California、アメリカ、90404
- 募集
- UCLA - Santa Monica /ID# 270621
-
-
Connecticut
-
New Haven、Connecticut、アメリカ、06510
- 募集
- Yale New Haven Hospital /ID# 270565
-
-
Florida
-
Orlando、Florida、アメリカ、32803
- 募集
- AdventHealth Orlando /ID# 270789
-
-
Georgia
-
Marietta、Georgia、アメリカ、30060
- 募集
- Northwest Georgia Oncology Centers /ID# 270245
-
-
Illinois
-
Chicago、Illinois、アメリカ、60637
- 募集
- University of Chicago Medical Center /ID# 271688
-
Hinsdale、Illinois、アメリカ、60521
- 募集
- Hope And Healing Cancer Services /ID# 271562
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- 募集
- Dana-Farber Cancer Institute /ID# 270624
-
-
Michigan
-
Ann Arbor、Michigan、アメリカ、48109-5000
- 募集
- University Of Michigan /ID# 270790
-
-
Missouri
-
Kansas City、Missouri、アメリカ、64111
- 募集
- Saint Lukes Hospital of Kansas City /ID# 270633
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68130
- 募集
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27514
- 募集
- University of North Carolina at Chapel Hill /ID# 267786
-
-
Ohio
-
Cincinnati、Ohio、アメリカ、45245
- 募集
- Oncology Hematology Care - Eastgate /ID# 271493
-
-
Texas
-
Austin、Texas、アメリカ、78705
- 募集
- Texas Oncology - Austin Midtown /ID# 271354
-
Webster、Texas、アメリカ、77598
- 募集
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355
-
-
Virginia
-
Fairfax、Virginia、アメリカ、22031
- 募集
- Virginia Cancer Specialists - Fairfax /ID# 271351
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- 募集
- University Of Washington /ID# 271298
-
-
-
-
-
Manchester、イギリス、M20 4BX
- 募集
- The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
-
-
Greater London
-
London、Greater London、イギリス、E1 2ES
- 募集
- Barts Health NHS Trust /ID# 271189
-
-
Oxfordshire
-
Oxford、Oxfordshire、イギリス、OX3 9DU
- 募集
- Oxford University Hospitals Nhs Foundation Trust /ID# 272486
-
-
Surrey
-
Sutton、Surrey、イギリス、SM2 5PT
- 募集
- The Royal Marsden - Sutton /ID# 271172
-
-
West Midlands
-
Birmingham、West Midlands、イギリス、B9 5SS
- 募集
- Heartlands Hospital - University Hospitals Birmingham /ID# 271178
-
-
-
-
-
Haifa、イスラエル、3109601
- 募集
- Rambam Health Care Campus- Haifa /ID# 268006
-
Jerusalem、イスラエル、9103102
- 募集
- Shaare Zedek Medical Center /ID# 268009
-
Jerusalem、イスラエル、91120
- 募集
- Hadassah Medical Center-Hebrew University /ID# 268007
-
-
Central District
-
Petah Tikva、Central District、イスラエル、4941492
- 募集
- Rabin Medical Center. /ID# 268008
-
-
Tel Aviv
-
Tel Aviv、Tel Aviv、イスラエル、6423906
- 募集
- Tel Aviv Sourasky Medical Center /ID# 268010
-
-
-
-
Milano
-
Milan、Milano、イタリア、20162
- 募集
- ASST Grande Ospedale Metropolitano Niguarda /ID# 269142
-
コンタクト:
- Site Coordinator
- メール:ctu.oncologia@ospedaleniguarda.it
-
-
Napoli
-
Naples、Napoli、イタリア、80138
- 募集
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
-
-
-
-
New South Wales
-
Sydney、New South Wales、オーストラリア、2109
- 募集
- Macquarie University /ID# 271514
-
-
Queensland
-
South Brisbane、Queensland、オーストラリア、4101
- 募集
- Mater Misericordiae /ID# 270694
-
コンタクト:
- Site Coordinator
- 電話番号:+61731632341
-
-
South Australia
-
Woodville South、South Australia、オーストラリア、5011
- 募集
- The Queen Elizabeth Hospital /ID# 270693
-
-
Victoria
-
Heidelberg、Victoria、オーストラリア、3084
- 募集
- Austin Health /ID# 270692
-
-
Western Australia
-
Nedlands、Western Australia、オーストラリア、6009
- 募集
- One Clinical Research /ID# 270695
-
-
-
-
-
Salzburg、オーストリア、5020
- 募集
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
-
Vienna、オーストリア、1090
- 募集
- Medizinische Universitaet Wien /ID# 268872
-
-
Styria
-
Graz、Styria、オーストリア、8010
- 募集
- Medizinische Universitaet Graz /ID# 268876
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2N 5G2
- 募集
- Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
-
Edmonton、Alberta、カナダ、T6G 1Z2
- 募集
- Cross Cancer Institute. /ID# 272711
-
-
Ontario
-
London、Ontario、カナダ、N6A 5W9
- 募集
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
-
Toronto、Ontario、カナダ、M5G 2M9
- 募集
- Princess Margaret Cancer Centre /ID# 268715
-
-
Quebec
-
Montreal、Quebec、カナダ、H1T 2M4
- 募集
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
-
-
-
-
-
Thessaloniki、ギリシャ、54639
- 募集
- Theagenio Cancer Hospital /ID# 269640
-
-
Attica
-
Chaïdári、Attica、ギリシャ、12462
- 募集
- University General Hospital Attikon /ID# 268555
-
Nea Kifissia、Attica、ギリシャ、14564
- 募集
- General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
-
Piraeus、Attica、ギリシャ、18547
- 募集
- Metropolitan Hospital /ID# 269636
-
-
Thessaloniki
-
Panórama、Thessaloniki、ギリシャ、55236
- 募集
- St. Luke's Hospital /ID# 269963
-
-
-
-
-
Barcelona、スペイン、08035
- 募集
- Hospital Universitario Vall de Hebron /ID# 270191
-
Madrid、スペイン、28027
- 募集
- Clinica Universidad de Navarra - Madrid /ID# 269754
-
Madrid、スペイン、28046
- 募集
- Hospital Universitario La Paz /ID# 269730
-
Valencia、スペイン、46010
- 募集
- Hospital Clinico Universitario de Valencia /ID# 269805
-
-
Cantabria
-
Santander、Cantabria、スペイン、39008
- 募集
- Hospital Universitario Marques de Valdecilla /ID# 269732
-
-
Navarre
-
Pamplona、Navarre、スペイン、31008
- 募集
- Clinica Universidad de Navarra - Pamplona /ID# 269753
-
-
-
-
-
Brno、チェコ、656 53
- 募集
- Masarykuv onkologicky ustav v Brne /ID# 268779
-
Hradec Králové、チェコ、500 05
- 募集
- Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
-
-
Praha 17
-
Prague、Praha 17、チェコ、128 00
- 募集
- Vseobecna Fakultni nemocnice v Praze /ID# 268775
-
-
Praha 5
-
Prague、Praha 5、チェコ、150 06
- 募集
- Fakultni nemocnice Motol a Homolka /ID# 268776
-
-
Praha, Hlavni Mesto
-
Prague、Praha, Hlavni Mesto、チェコ、140 59
- 募集
- Fakultni Thomayerova nemocnice /ID# 269632
-
-
-
-
-
Paris、フランス、75015
- 募集
- Hopital Europeen Georges Pompidou /ID# 270224
-
-
Hauts-de-France
-
Lille、Hauts-de-France、フランス、59037
- 募集
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
-
-
New Aquitaine
-
Poitiers、New Aquitaine、フランス、86021
- 募集
- Centre Hospitalier Universitaire de Poitiers /ID# 270225
-
-
Pays de la Loire Region
-
Nantes、Pays de la Loire Region、フランス、44000
- 募集
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
-
-
Île-de-France Region
-
Paris、Île-de-France Region、フランス、75013
- 募集
- Hopital Pitie Salpetriere /ID# 270220
-
-
-
-
-
São Paulo、ブラジル、04014-002
- 募集
- Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
-
São Paulo、ブラジル、01401-002
- 募集
- Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
-
-
Estado de Bahia
-
Salvador、Estado de Bahia、ブラジル、41253-190
- 募集
- Hospital Sao Rafael /ID# 271681
-
-
Rio Grande do Sul
-
Ijuí、Rio Grande do Sul、ブラジル、98700-000
- 募集
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
-
-
São Paulo
-
Barretos、São Paulo、ブラジル、14784-400
- 募集
- Hospital De Amor /ID# 271874
-
São José do Rio Preto、São Paulo、ブラジル、15090-000
- 募集
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
-
-
-
-
-
Rio Piedras、プエルトリコ、00935
- 募集
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
-
San Juan、プエルトリコ、00917-5022
- 募集
- Puerto Rico Medical Research Center /ID# 268825
-
-
-
-
-
Kaohsiung City、台湾、807
- 募集
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
-
Kaohsiung City、台湾、833
- 募集
- Kaohsiung Chang Gung Memorial Hospital /ID# 269726
-
Tainan、台湾、704
- 募集
- National Cheng Kung University Hospital /ID# 270835
-
Taipei、台湾、112
- 募集
- Taipei Veterans General Hospital /ID# 269718
-
Taipei、台湾、100
- 募集
- National Taiwan University Hospital /ID# 269717
-
Taoyuan City、台湾、333
- 募集
- Linkou Chang Gung Memorial Hospital /ID# 269725
-
-
-
-
Aichi-ken
-
Nagoya、Aichi-ken、日本、464-8681
- 募集
- Aichi Cancer Center /ID# 270113
-
-
Chiba
-
Kashiwa-shi、Chiba、日本、277-8577
- 募集
- National Cancer Center Hospital East /ID# 270114
-
-
Kanagawa
-
Kawasaki-shi、Kanagawa、日本、216-8511
- 募集
- St Marianna University School Of Medicine /ID# 270111
-
-
Miyagi
-
Sendai、Miyagi、日本、980-8574
- 募集
- Tohoku University Hospital /ID# 270966
-
-
Tokyo
-
Chuo-Ku、Tokyo、日本、104-0045
- 募集
- National Cancer Center Hospital /ID# 270112
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Exclusion Criteria:
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Substudy 1: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
実験的:Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
実験的:Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
実験的:Substudy 1: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
実験的:Substudy 2: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
実験的:Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
実験的:Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
実験的:Substudy 2: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration. |
IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection IV Infusion |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
時間枠:Up to 24 Weeks
|
OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1. |
Up to 24 Weeks
|
|
Number of Participants with Adverse Events (AE)s
時間枠:Up to Approximately 6 Years
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 6 Years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
時間枠:Up to 22 Months
|
PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier. |
Up to 22 Months
|
|
Duration of Response (DOR) as Assessed by the investigator
時間枠:Up to 14 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first. |
Up to 14 Months
|
|
Overall Survival (OS)
時間枠:Up to Approximately 6 Years
|
OS is defined as the time from first dose of study treatment to the event of death from any cause. |
Up to Approximately 6 Years
|
|
Disease Control (DC) as Assessed by the Investigator
時間枠:Up to Approximately 6 Years
|
DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator. |
Up to Approximately 6 Years
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:ABBVIE INC.、AbbVie
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
- 部位別新生物
- 新生物
- 腸の病気
- 消化器腫瘍
- 消化器系腫瘍
- 消化器系疾患
- 消化器疾患
- 腸の腫瘍
- 直腸疾患
- 結腸疾患
- 結腸直腸腫瘍
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- 酵素と補酵素
- 抗体、モノクローナル、ヒト化
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 調整錯体
- ピリミジン
- ホルミルテトラヒドロフォレート
- テトラヒドロフォレート
- 葉酸
- 羽毛
- プテリジン
- ウラシル
- ピリミジノン
- コエンザイム
- オキサリプラチン
- ベバシズマブ
- パニツムマブ
- フルオロウラシル
- ロイコボリン
その他の研究ID番号
- M24-533
- EU CT (その他の識別子:2024-512981-33-00)
- 2024-512981-33-00 (Ctis)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
IPD 共有時間枠
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
IPD 共有アクセス基準
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。